These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
    Author: Möller P, Wittig B, Schadendorf D.
    Journal: Anticancer Res; 1998; 18(2B):1237-41. PubMed ID: 9615794.
    Abstract:
    We describe a 52-year old man with a confined massive subcutaneous and intramuscular tumor metastasis on his back. He was treated with tumor-infiltrating lymphocytes (TIL) which were gained from the tumor of his back 3 months previously. Between 2.5 x 10(7) and 2 x 10(8) TIL were administered, five times at 2-week-intervals on day 2 in combination with a continuous subcutaneous infusion of interleukin(IL)-2 (1.8 x 10(6) IE/24 hours) over 3 days and a single intratumoral injection of a low dose of interferon(IFN)-alpha (1 x 10(6) IE) on day 1. There were no severe side effects. Immunotherapy led to a consistent regression of the tumor mass. After 3 months, treatment was discontinued due to the development of intracranial metastases. In parallel, due to an erythematous induration at the infusion site, it became increasingly difficult to infuse IL-2 subcutaneously. Additionally, high titers of anti-IL-2-antibodies were detected in serum. Following cessation of the immunotherapy and brain irradiation, the patient's clinical course has remained stable over the past 5 months, suggesting that small amounts of TIL with a low-dosed IL-2 may be helpful in the treatment of local tumor masses.
    [Abstract] [Full Text] [Related] [New Search]